journal article·2019-12-04Open access

The role of DRP1 in ropivacaine-induced mitochondrial dysfunction and neurotoxicity

Yan Chen, Lili Yan, Yan Zhang, Xianhui Yang

Abstract

Ropivacaine is a commonly used local anaesthetic, but its side effects remain largely unknown. In the present study, we investigated the side effects of ropivacaine in human neuronal SH-5Y5Y cells. We show that 0.5% and 1% ropivacaine could cause fission-like mitochondrial morphological changes. Ropivacaine exclusively induces mitochondrial fission protein DRP1, generation of ROS and causes mitochondrial dysfunction including decreasing mitochondrial membrane potential, the activity of cytochrome C oxidase and ATP production. The side effects of ropivacaine appear to be dependent on DRP1 expression as silencing of DRP1 in neuronal cells abolishes ropivacaine-induced morphological changes and mitochondrial dysfunction. Silencing of DRP1 prevents ropivacaine-induced cellular LDH release and cell death. Moreover, DRP1-deficient neuronal cells are resistant to ropivacaine-induced apoptosis and silencing of DRP1 rescues the activity of cytochrome C oxidase and cellular ATP production. Collectively, our data indicate that imbalances in mitochondrial dynamics, mitochondrial dysfunction and cell death resulting from ropivacaine are all dependent on DRP1 expression. Our study provides valuable data to assess the safety of ropivacaine.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Anesthesia and Pain Management · Anesthesia and Neurotoxicity Research · Cardiac Ischemia and Reperfusion

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of anesthesiology, Second Affiliated Hospital of Zhengzhou University

Department of outpatient service, Second Affiliated Hospital of Zhengzhou Universitys

References (47)

Show source-provided references
1. 10.1093/bja/aep31010.1093/bja/aep310 ↗
2. 10.2344/0003-3006-59.2.9010.2344/0003-3006-59.2.90 ↗
3. Shipton EA. New formulations of local anaesthetics-part I. Anesthesiol Res Pract. 2012;2012:546409.
4. 10.1097/EJA.000000000000013710.1097/EJA.0000000000000137 ↗
5. 10.3390/ijms1703033910.3390/ijms17030339 ↗
6. 10.1002/ams2.26510.1002/ams2.265 ↗
7. 10.1093/bja/aep23610.1093/bja/aep236 ↗
8. 10.1213/ANE.0b013e318266f3d910.1213/ANE.0b013e318266f3d9 ↗
9. 10.1016/j.ejphar.2018.05.03410.1016/j.ejphar.2018.05.034 ↗
10. 10.1007/s00540-018-2506-810.1007/s00540-018-2506-8 ↗
11. 10.1016/j.bpa.2004.12.00310.1016/j.bpa.2004.12.003 ↗
12. 10.1097/ALN.000000000000017410.1097/ALN.0000000000000174 ↗
13. 10.1038/scientificamerican0757-13110.1038/scientificamerican0757-131 ↗
14. 10.1016/j.mito.2016.07.00310.1016/j.mito.2016.07.003 ↗
15. 10.3390/antiox702003010.3390/antiox7020030 ↗
16. Gong Q, Wen X, Li H, et al. Up-regulation of Cav3.1 expression in SH-SY5Y cells induced by lidocaine hydrochloride. Artif Cells Nanomed Biotechnol. 2018;12:1–8.
17. 10.3109/21691401.2015.110100010.3109/21691401.2015.1101000 ↗
18. 10.1111/j.1471-4159.2011.07581.x10.1111/j.1471-4159.2011.07581.x ↗
19. 10.1186/s13045-018-0554-z10.1186/s13045-018-0554-z ↗
20. 10.1007/s12192-017-0828-310.1007/s12192-017-0828-3 ↗
21. 10.1093/hmg/ddy33510.1093/hmg/ddy335 ↗
22. 10.1074/jbc.M109.03577410.1074/jbc.M109.035774 ↗
23. 10.1007/s12192-015-0642-810.1007/s12192-015-0642-8 ↗
24. 10.1007/s12192-015-0613-010.1007/s12192-015-0613-0 ↗
25. 10.1177/15440591050840091410.1177/154405910508400914 ↗
26. 10.1016/j.bbadis.2015.12.01810.1016/j.bbadis.2015.12.018 ↗
27. 10.1093/hmg/ddw31210.1093/hmg/ddw312 ↗
28. Manczak M, Kandimalla R, Fry D, et al. Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum Mol Genet 2016;25:5148–5166.
29. 10.1097/00000542-200206000-0002310.1097/00000542-200206000-00023 ↗
30. 10.1017/S146239941000145610.1017/S1462399410001456 ↗
31. 10.1136/rapm-00115550-199722021-0007010.1136/rapm-00115550-199722021-00070 ↗
32. 10.1097/00000542-199906000-0004010.1097/00000542-199906000-00040 ↗
33. 10.1136/rapm-00115550-199924020-0001410.1136/rapm-00115550-199924020-00014 ↗
34. 10.1097/00000542-200012000-0003110.1097/00000542-200012000-00031 ↗
35. 10.1093/bja/87.5.78410.1093/bja/87.5.784 ↗
36. 10.1016/j.jclinane.2003.07.01210.1016/j.jclinane.2003.07.012 ↗
37. 10.1007/BF0302679610.1007/BF03026796 ↗
38. Rodolà F, Anastasi F, Vergari A. Ropivacaine induced acute neurotoxicity after epidural injection. Eur Rev Med Pharmacol Sci. 2007;11:133–135.
39. 10.1345/aph.1P76010.1345/aph.1P760 ↗
40. 10.1213/00000539-198912000-0001910.1213/00000539-198912000-00019 ↗
41. 10.1177/0310057X090370061210.1177/0310057X0903700612 ↗
42. 10.1213/ANE.0b013e3181de574e10.1213/ANE.0b013e3181de574e ↗
43. 10.3109/00498254.2013.78245410.3109/00498254.2013.782454 ↗
44. 10.1097/ALN.000000000000200310.1097/ALN.0000000000002003 ↗
45. 10.1097/00000542-199805000-0002610.1097/00000542-199805000-00026 ↗
46. 10.2106/JBJS.H.0184710.2106/JBJS.H.01847 ↗
47. 10.1016/j.joca.2015.05.01310.1016/j.joca.2015.05.013 ↗